CAMBRIDGE, Mass., May 20, 2024 (GLOBE NEWSWIRE) — Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a biopharmaceutical company focused on developing a new class of genetic medicines for both rare and highly prevalent diseases, is presenting new preclinical data demonstrating the specificity and the completion of a genetic mouse study and sustained editing activity for KRRO-110, its development candidate for the treatment of AATD.
Korro Presents Additional Preclinical Data for KRRO-110 at the American Thoracic Society 2024 International Conference
Home »
Korro Presents Additional Preclinical Data for KRRO-110 at the American Thoracic Society 2024 International Conference
Ähnliche Beiträge
Trump Offloads Ebola-Infected American Citizen to Germany
Berlin/Washington (LabNews Media LLC) – A U.S. medical missionary infected with the Bundibugyo strain of Ebola virus disease (EVD) has been evacuated to Berlin’s Charité…
Kanada investiert 6,8 Millionen Dollar in KI-Projekte in Alberta
Edmonton (LabNews Media LLC) – Die kanadische Bundesregierung fördert fünf Projekte in Alberta mit insgesamt 6,8 Millionen Dollar über die Regional Artificial Intelligence Initiative (RAII).…
Ebola in Deutschland: Kaum Sonderisoliertstationen (SIS)
Berlin (LabNews Media LLC) – Die Weltgesundheitsorganisation (WHO) hat den Ebola-Ausbruch mit der Bundibugyo-Variante in der Demokratischen Republik Kongo und Uganda als internationale gesundheitliche Notlage…
